Polar Solvents Decrease the Viscosity of High Concentration IgG1 Solutions Through Hydrophobic Solvation and Interaction: Formulation and Biocompatibility Considerations-Reference-Cited by-同舟云学术

Polar Solvents Decrease the Viscosity of High Concentration IgG1 Solutions Through Hydrophobic Solvation and Interaction: Formulation and Biocompatibility Considerations

Published:2013-04 Issue:4 Volume:102 Page:1182-1193
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Kamerzell Tim J.,Pace Amanda L.,Li Megan,Danilenko Dimitry M.,Mcdowell Michelle,Gokarn Yatin R.,John Wang Y.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference40 articles.

1. Formulation and manufacturability of biologics;Shire;Curr Opin Biotechnol,2009

2. Challenges in the development of high protein concentration formulations;Shire;J Pharm Sci,2004

3. Specific interactions in high concentration antibody solutions resulting in high viscosity;Yadav;J Pharm Sci,2010

4. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties;Kamerzell;J Phys Chem B,2009

5. Reversible selfassociation of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity;Kanai;J Pharm Sci,2008

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

2. Stability of Protein Pharmaceuticals: Recent Advances;Pharmaceutical Research;2024-06-27

3. Application of Formulation Principles to Stability Issues Encountered During Processing, Manufacturing, and Storage of Drug Substance and Drug Product Protein Therapeutics;Journal of Pharmaceutical Sciences;2023-11

4. Random Heteropolymer Excipients Improve the Colloidal Stability of a Monoclonal Antibody for Subcutaneous Administration;Pharmaceutical Research;2022-11-15

5. Advanced Formulations/Drug Delivery Systems for Subcutaneous Delivery of Protein-Based Biotherapeutics;Journal of Pharmaceutical Sciences;2022-11